Case Study: Technology Transfer of a Legacy Peptide Product from an Innovator Site to a CDMO
Introduction: Peptide technology transfer to a CDMO is more than transferring a manufacturing recipe — it requires transfer of product, […]
Case Study: Generic Ophthalmic Suspension ANDA Development — Sterile Fill, Container Closure, and BE Strategy
Introduction Executing Generic Ophthalmic Suspension ANDA Development requires a comprehensive technical strategy that integrates qualitative and quantitative formulation sameness (Q1/Q2),
Impurity Control Strategies Under ICH Q3A and Q3B for Generic Drug ANDA Submissions
Introduction Impurity Control Strategies Under ICH Q3A and Q3B establish a risk-based regulatory framework used by global health authorities to
Impurity Control Strategies Under ICH Q3A and Q3B for Generic Drug ANDA Submissions Read More »
Outsourcing Your First Generic Drug Project to a CDMO: A Step-by-Step Sponsor Guide
Introduction Outsourcing your first generic drug project to a CDMO requires a structured technical transition that covers candidate characterization, technology
Outsourcing Your First Generic Drug Project to a CDMO: A Step-by-Step Sponsor Guide Read More »
Container Closure System Selection and Qualification for Generic Injectable ANDA at a CDMO
Introduction Container Closure System Selection and Qualification for generic parenteral drug products involves the systematic evaluation and validation of primary
Case Study: End-to-End ANDA Analytical Package Development for a Complex Generic Suspension
Introduction End-to-End ANDA Analytical Package Development for a complex generic suspension requires an integrated analytical framework that connects qualitative (Q1)
Preparing for an FDA or Health Canada Inspection: Your Testing Lab’s Role
Introduction: FDA and Health Canada Inspection Readiness for Testing Laboratories means maintaining a laboratory in a state where analytical activities,
Preparing for an FDA or Health Canada Inspection: Your Testing Lab’s Role Read More »
Technology Transfer from Innovator to Generic CDMO: Process, Pitfalls, and Best Practices
Introduction Technology Transfer from Innovator to Generic CDMO is a structured and highly regulated process involving the systematic translation of
Bioanalytical CRO Services for Phase I First-in-Human Studies: Regulatory Requirements and Study Design
Introduction Bioanalytical CRO services for Phase I First-in-Human studies provide the quantitative bioanalytical infrastructure necessary to validate drug concentration assays,
Case Study: Nitrosamine Risk Assessment for a Proton Pump Inhibitor Seeking ANDA Approval
Introduction A comprehensive Nitrosamine Risk Assessment for a Proton Pump Inhibitor seeking Abbreviated New Drug Application (ANDA) approval requires a